These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10615348)

  • 1. Risks associated with the inappropriate use of naltrexone in the treatment of opioid dependence.
    Latt NC
    Med J Aust; 1999 Nov; 171(9):500-1. PubMed ID: 10615348
    [No Abstract]   [Full Text] [Related]  

  • 2. Active surveillance of adverse events associated with naltrexone in New South Wales.
    Thackway SV; Ward PL; Taylor LK
    Med J Aust; 1999 Nov; 171(9):499-500. PubMed ID: 10615347
    [No Abstract]   [Full Text] [Related]  

  • 3. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.
    Miotto K; McCann MJ; Rawson RA; Frosch D; Ling W
    Drug Alcohol Depend; 1997 Apr; 45(1-2):131-4. PubMed ID: 9179515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone in the treatment of opioid dependence.
    George S; Ekhtiari H
    Br J Hosp Med (Lond); 2010 Oct; 71(10):568-70. PubMed ID: 21085073
    [No Abstract]   [Full Text] [Related]  

  • 5. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
    Degenhardt L; Gibson A; Mattick RP; Hall W
    Drug Alcohol Rev; 2008 Jan; 27(1):1-3. PubMed ID: 18034375
    [No Abstract]   [Full Text] [Related]  

  • 6. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
    Poser W; Ehrenreich H
    Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in opioid antagonist treatment for opioid addiction.
    Ling W; Mooney L; Wu LT
    Psychiatr Clin North Am; 2012 Jun; 35(2):297-308. PubMed ID: 22640757
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
    Brewer C
    Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
    [No Abstract]   [Full Text] [Related]  

  • 10. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The development of coma after the use of naltrexone in a patient with opioid addiction].
    Sivolap IuP; Savchenkov VA; Mishnaevskiĭ AL; Iakovchuk AM; Rasulov MM; Kaludzherovich LV; Parfenov DA; Mustafin KhKh
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(8):55-7. PubMed ID: 10983373
    [No Abstract]   [Full Text] [Related]  

  • 12. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid opioid detoxification in Australia.
    Reece S
    Acad Emerg Med; 2002 Sep; 9(9):960-2. PubMed ID: 12208687
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid opioid detoxification in Australia.
    O'Neil G; Hulse G; Armstrong J; Little M; Murray L
    Acad Emerg Med; 2002 Sep; 9(9):960. PubMed ID: 12208688
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe opioid withdrawal syndrome after a single dose of nalmefene.
    Donnerstag N; Schneider T; Lüthi A; Taegtmeyer A; Raetz Bravo A; Mehlig A
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1025-6. PubMed ID: 26050241
    [No Abstract]   [Full Text] [Related]  

  • 19. [Alcohol consumption in opioid-dependence patients in treatment with naltrexone].
    Ochoa Mangado E; Arias Horcajadas F
    Actas Esp Psiquiatr; 2000; 28(4):239-49. PubMed ID: 11116795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-dependent error processing.
    Fellows-Smith J
    J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.